Literature DB >> 2827831

Diminished IL-2-induced gamma-interferon production by unstimulated peripheral-blood lymphocytes in rheumatoid arthritis.

F Hasler1, J M Dayer.   

Abstract

A diminished gamma-interferon (IFN-gamma) production by T cells from patients with rheumatoid arthritis (RA) in response to autologous stimulation coincides with a defective regulation of Epstein-Barr virus (EBV) transformation and is in part due to monocyte-produced interleukin-1 (IL-1) inhibitor and prostaglandins. Since IL-2 can act directly on unstimulated T-cells to induce IFN-gamma production we have now examined the effect of recombinant IL-2 (rIL-2) on purified resting T lymphocytes from RA patients. Treatment with rIL-2(25 U/ml) of lymphocytes from 15 controls led to an increased production of 72-h supernatant EBV-inhibitory activity (19 +/- 4% SE without; 48 +/- 7% with rIL-2), but had only minimal or no effect on gamma-interferon production by E-rosetting lymphocytes from 15 patients with active RA. This defect could not be corrected by adding indomethacin to RA cultures.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2827831     DOI: 10.1093/rheumatology/27.1.15

Source DB:  PubMed          Journal:  Br J Rheumatol        ISSN: 0263-7103


  4 in total

Review 1.  Cytokines and proteoglycans.

Authors:  J J Nietfeld
Journal:  Experientia       Date:  1993-05-15

2.  Modulation of human T cell functions by surface sulphydryl groups: differential effects on IL-2 production and responsiveness.

Authors:  S Smith; C H Brown-Galatola; N D Hall
Journal:  Clin Exp Immunol       Date:  1992-04       Impact factor: 4.330

3.  Quantitation of IL-2Rp75 (CD122) expression on mononuclear cells in rheumatic disease.

Authors:  P Creamer; N D Hall
Journal:  Ann Rheum Dis       Date:  1996-11       Impact factor: 19.103

4.  In vitro production of interferon-gamma by peripheral blood from patients with Graves' disease, Hashimoto's thyroiditis and rheumatoid arthritis.

Authors:  S Matsubayashi; F Akasu; Y Kasuga; K Snow; E Keystone; R Volpé
Journal:  Clin Exp Immunol       Date:  1990-10       Impact factor: 4.330

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.